Free Trial

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx logo
$77.33 -4.70 (-5.73%)
(As of 02:46 PM ET)

Arcellx - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
15

Based on 15 Wall Street analysts who have issued ratings for Arcellx in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 13 have given a buy rating, and 2 have given a strong buy rating for ACLX.

Consensus Price Target

$105.93
36.98% Upside
According to the 15 analysts' twelve-month price targets for Arcellx, the average price target is $105.93. The highest price target for ACLX is $136.00, while the lowest price target for ACLX is $73.00. The average price target represents a forecasted upside of 36.98% from the current price of $77.33.
Get the Latest News and Ratings for ACLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Arcellx and its competitors.

Sign Up

ACLX Analyst Ratings Over Time

TypeCurrent Forecast
12/19/23 to 12/18/24
1 Month Ago
11/19/23 to 11/18/24
3 Months Ago
9/20/23 to 9/19/24
1 Year Ago
12/19/22 to 12/19/23
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
14 Buy rating(s)
12 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$105.93$103.08$78.00$52.23
Forecasted Upside36.98% Upside16.84% Upside-8.70% Downside0.25% Upside
Consensus Rating
Buy
Buy
Buy
Buy

ACLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Arcellx Stock vs. The Competition

TypeArcellxMedical CompaniesS&P 500
Consensus Rating Score
3.13
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside37.00% Upside28,685.97% Upside11.91% Upside
News Sentiment Rating
Positive News

See Recent ACLX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/10/2024UBS Group
4 of 5 stars
 Boost TargetBuy ➝ Buy$106.00 ➝ $114.00+35.31%
12/10/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$115.00 ➝ $115.00+38.64%
12/9/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$105.00 ➝ $105.00+24.19%
11/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Lawson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
11/12/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$87.00 ➝ $136.00+32.36%
11/8/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$91.00 ➝ $115.00+15.97%
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.
11/6/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$77.00 ➝ $106.00+21.67%
11/6/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$84.00 ➝ $100.00+14.78%
11/6/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$81.00 ➝ $106.00+21.67%
10/18/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ben Burnett
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$83.00 ➝ $122.00+28.60%
10/17/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$85.00 ➝ $115.00+25.68%
10/8/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Q. Ding
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$109.00+43.29%
9/9/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Bienkowski
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
5/14/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$85.00+70.79%
4/4/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$82.00+29.75%
10/30/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
10/12/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/24/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$45.00 ➝ $58.00+45.22%
3/30/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$35.00 ➝ $39.00+27.74%
3/30/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$35.00 ➝ $39.00+25.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:07 PM ET.


ACLX Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Arcellx is $105.93, with a high forecast of $136.00 and a low forecast of $73.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 13 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACLX shares.

According to analysts, Arcellx's stock has a predicted upside of 36.98% based on their 12-month stock forecasts.

Over the previous 90 days, Arcellx's stock had 1 upgrade by analysts.

Analysts like Arcellx more than other "medical" companies. The consensus rating for Arcellx is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ACLX compares to other companies.


This page (NASDAQ:ACLX) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners